Related Experiment Video
Updated: Jun 18, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
A meta-analysis on XRCC1 and XRCC3 polymorphisms and colorectal cancer risk
Zheng Jiang1, Chunxiang Li, Ye Xu
1Department of Colorectal Surgery, Cancer Hospital, Fudan University, 270 Dong An Road, Shanghai 200032, China.
Purpose:
Studies on polymorphism of X-ray repair cross-complementing group 1 (XRCC1), group 3 (XRCC3), and colorectal cancer risk are inconclusive. The purpose of this study is to evaluate the role of XRCC1 R399Q, R194W, and XRCC3 T241M genotypes in colorectal cancer susceptibility.
Methods:
We performed a meta-analysis on all available studies that provided 3,514/4,686 cases/controls for R399Q, 2,767/3,907 cases/controls for R194W and 3,183/3,926 cases/controls for T241M.
Results:
Overall, no apparent effects of 194 W allele compared to 194R on colorectal cancer risk were found in all subjects and subgroups (Asians and Caucasians). Insignificant effects were also found under other genetic contrasts (homologous contrast, dominant model, and recessive model). The same pattern of results was produced in T241M polymorphism. The 399Q allele compared to 399R showed no significant association with colorectal cancer risk in all subjects and subgroups. However, protective effects of 399QQ genotype were observed under recessive model (QQ/QR + RR) [P = 0.02, OR = 0.84, 95% CI (0.72, 0.97)] and homozygote contrast (QQ/RR) [P = 0.01, OR = 0.81; 95% CI (0.69, 0.95)] in all subjects.
Conclusion:
Results suggested that 399Q allele might act as a recessive allele in its association with colorectal cancer.
Related Concept Videos
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Inflammatory Bowel Disease III: Crohn's Disease